Please assess the completion status of the following clinical trial:

Trial Title: A Non-inferiority, Multicenter and Randomized, Multiple-Dose Study About a Treatment to Hypolactasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* To have participated in the single-dose clinical study (EF099) previously performed, with the clinical response being considered as satisfactory by the investigator~* The patient should be a male or female, aged between 18 and 60 years old~* Have a medical history consistent with lactose intolerance, confirmed by the test of hydrogen in the expired air~* The female patients should agree to use birth control methods during the study participation~* To be able to meet the study instructions and all the visits required~* To give a free consent to participate in the study and sign the informed consent form (ICF).~Exclusion Criteria:~* Smoking~* Secondary hypolactasia~* Gastrointestinal inflammatories diseases - present diverticular disease, diabetic gastropathy or neoplasias~* Colonoscopy or colon cleaning procedure 4 weeks before the start of study~* Latrogenic: unnoticed intake of laxatives in over-the-counter drugs or alternative medicine, intake of cereal bran or probiotics~* Diagnosis of HIV, immunodepression of any origin, or cancer under treatment.~* Diagnosis of other comorbidity that, at the investigator's discretion, may compromise the study participation (e.g., systemic infection during the study or use of antibiotics in the last 4 weeks, diabetes mellitus, uncontrolled hypertension or renal failure),~* Hypersensitivity or previous laboratory or clinical adverse event related to the use of lactase or any of the components of the formulations used in the study~* Incapacity to understand and complete the study questionnaires, including the questions that require the use of the Visual Analogue Scale and ICF~* Pregnancy or lactation~* Use of alcohol, exceeding 3 doses daily~* Participation in another clinical study on the last 12 months~* Patient having some chronic pulmonary disease that, in the investigator's opinion, may harm or interfere with the expired hydrogen test (e.g., cystic fibrosis).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Lactase EUF (Type: EXPERIMENTAL): 1 oral tablet of the test drug before breakfast, lunch and dinner for 42 consecutive days
- Lactase Ref (Type: ACTIVE_COMPARATOR): 1 oral tablet of the comparative drug before breakfast, lunch and dinner for 42 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).